(NASDAQ: MPLT) Maplight Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.65%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.72%.
Maplight Therapeutics's earnings in 2026 is N/A.On average, 16 Wall Street analysts forecast MPLT's earnings for 2026 to be -$237,012,779, with the lowest MPLT earnings forecast at -$253,300,946, and the highest MPLT earnings forecast at -$206,640,246. On average, 15 Wall Street analysts forecast MPLT's earnings for 2027 to be -$191,014,126, with the lowest MPLT earnings forecast at -$241,746,868, and the highest MPLT earnings forecast at -$4,761,296.
In 2028, MPLT is forecast to generate -$212,802,723 in earnings, with the lowest earnings forecast at -$245,301,969 and the highest earnings forecast at -$176,167,951.